

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/587,249	07/26/2006	Tomoharu Nishioka	SPL-06-1211	9642
35811 IP GROUP OF	7590 05/19/2011 F DLA PIPER LLP (US)	EXAMINER		
ONE LIBERT	Y PLACE	KASHNIKOW, ERIK		
	T ST, SUITE 4900 IIA. PA 19103		ART UNIT	PAPER NUMBER
			1782	
			NOTIFICATION DATE	DELIVERY MODE
			05/19/2011	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail  $\,$  address(es):

pto.phil@dlapiper.com

## **Advisory Action** Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)		
	10/587,249	NISHIOKA ET AL.		
	Examiner	Art Unit		
	ERIK KASHNIKOW	1782		

	ENIK KASHINIKOW	1702						
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress					
THE REPLY FILED 06 May 2011 FAILS TO PLACE THIS APPI	LICATION IN CONDITION FOR AL	LOWANCE.						
. ☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
<ul> <li>a) The period for reply expires 4 months from the mailing date</li> </ul>								
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.								
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TW MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.138(a). The data have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as					
2. The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two months	s of the date of					
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).								
AMENDMENTS								
<ol> <li>The proposed amendment(s) filed after a final rejection, to         <ul> <li>They raise new issues that would require further core</li> <li>They raise the issue of new matter (see NOTE belowed)</li> </ul> </li> </ol>	sideration and/or search (see NO		cause					
(c) They are not deemed to place the application in bett appeal; and/or		ducing or simplifying ti	he issues for					
(d) They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reject	ected claims.						
4. The amendments are not in compliance with 37 CFR 1.12	1 See attached Notice of Non-Co.	mnliant Amendment (	PTOI -324)					
5. Applicant's reply has overcome the following rejection(s):		inpliant runorialitori (	TOL OLY).					
Diagnostics reply has overcome the browning rejection(s).      would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).								
<ol> <li>For purposes of appeal, the proposed amendment(s): a) [     how the new or amended claims would be rejected is proving the company of the compa</li></ol>		l be entered and an e	xplanation of					
The status of the claim(s) is (or will be) as follows:								
Claim(s) allowed: Claim(s) objected to:								
Claim(s) rejected:								
Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE								
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>								
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome all rejections under appea	al and/or appellant fail:	s to provide a					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after en	ntry is below or attach	ed.					
The request for reconsideration has been considered but See below.	does NOT place the application in	condition for allowan	ce because:					
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).								
13. Other:								
/Rena L. Dye/ Supervisory Patent Examiner, Art Unit 1782								

With regards to applicants arguments regarding the main component of the rejection. The examiner respectfully disagrees that it is clear from the claims that the main component of applicants semi aromatic polyamide are diamines and dicarboxylic acids. The claim as written only requires that the specific diamines and dicarboxylic units mentioned in the claim are the main diamine and dicarboxylic units, however clearly leaves open the possibility of the presence of other units that are not diamines or dicarboxylic acids, such as dodecane lactam, which may be present in concentrations greater than the diamine units. It is further noted that applicants can not solely look to examples, but rather must look at what the prior art as a whole teaches. While the examples of Nishi teach adipic acid and m-xylylendiamine, the specification further teaches the instantivi claimed dicarboxylic acids and diamines.